Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
-
Published:2024-07
Issue:7
Volume:9
Page:103625
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Saleh M.ORCID,
Barve M.ORCID,
Subbiah V.,
Papadopoulos K.P.,
Morgensztern D.ORCID,
Mettu N.B.,
Roychowdhury S.ORCID,
Spanggaard I.ORCID,
Veronese M.L.,
Tian C.,
Silverman I.M.ORCID,
Gutierrez M.
Funder
Incyte Corporation